Updated Guidance Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe RSV Infection During the 2022-2023 RSV Season

The American Academy of Pediatrics encourages the use of palivizumab in eligible patients with RSV. This webpage provides guidance on dosage and and includes links to related resources.
Rate: Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.